Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | VHL N78K |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
VHL N78K | clear cell renal cell carcinoma | predicted - sensitive | Belzutifan | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic clear cell renal cell carcinoma harboring VHL N78K responded to treatment with Welireg (belzutifan) as a second-line therapy (PMID: 38344974). | 38344974 |